PCTL Targets $36.16 Billion HAI Market…
A Hospital Acquired Infection (HAI) or nosocomial infection or Health Care Associated Infection (HCAI), is an infection that is acquired in a health care facility.
The global market for Hospital Acquired Infections (HAI) was $23.7 Billion in 2016 and is expected to reach around $36.16 Billion by the end of the forecast period (2022) growing at a Compounded Annual Growth Rate (CAGR) of 7.3%.
North America (United States & Canada) holds the largest share in the global Hospital Acquired Infections market followed by Europe (including the United Kingdom) and Asia Pacific, respectively.
In the United States, the Centers for Disease Control and Prevention estimated roughly 1.7 million hospital-associated infections, from all types of microorganisms, including bacteria and fungi combined, cause or contribute to 99,000 deaths each year.
Paradigm Convergence Technologies Corporation (OTC Pink: PCTL) goal is to provide solutions to this issue, by outfitting a healthcare setting with the technology and guidance needed to effectively get the job done.
PCTL’s flagship product, years in the research and development stage, is the patented Annihilyzer® Infection Control System which is now in use in the United States and has been tested, accepted and deployed for use in the United Kingdom.
PCTL and the Covid-19 Pandemic
The Covid-19 Pandemic has affected our day to day lives in profound ways and has taken a huge toll on businesses around the world… but that is not the case in regards to PCT Ltd.
Since PCT Ltd obtained EPA Approval on 26 March 2020 for Emerging Pathogens Labeling for use Against SARS-CoV-2, the novel coronavirus that causes the disease COVID-19, business has been booming.
Why you ask? The answer is simple… One of the fluids generated by the Annihilyzer® Infection Control System and by PCTL’s large volume Green Seal Certified generators, Hydrolyte®, has demonstrated effectiveness against viruses similar to the SARS-CoV-2 virus on hard, non-porous surfaces. Therefore, Hydrolyte® can be used against the SARS-CoV-2 virus when used in accordance with the directions for use against Norovirus and Rhinovirus type 16 on hard, non-porous surfaces. You can refer to the CDC website for additional information.
Bottom line, Paradigm Convergence Technologies Corporation (OTC Pink: PCTL) is a company in the Right Place at the Right Time with the Right Product and has a First Movers Advantage in this new world we find ourselves in.
But don’t take my word for it. If you do your own Due Diligence I think you will agree, PCTL is an emerging player in a Multi-Billion Dollar market that should provide a very healthy ROI for those investors with a vision of the future.
DE
Anything written herein that you find Misspelled, Objectionable, Incoherent, Dim-Witted, Plagiarized or Legally Actionable should be attributed to the Keyboard Manufacturer, Russian Hackers, Jack Daniels (the drink not the person) or the DNC.
